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Abstract: Many neurodegenerative and inherited metabolic diseases frequently compromise nervous
system function, and mitochondrial dysfunction and oxidative stress have been implicated as key
events leading to neurodegeneration. Mitochondria are essential for neuronal function; however,
these organelles are major sources of endogenous reactive oxygen species and are vulnerable targets
for oxidative stress-induced damage. The brain is very susceptible to oxidative damage due to
its high metabolic demand and low antioxidant defence systems, therefore minimal imbalances in
the redox state can result in an oxidative environment that favours tissue damage and activates
neuroinflammatory processes. Mitochondrial-associated molecular pathways are often compromised
in the pathophysiology of neurodegeneration, including the parkin/PINK1, Nrf2, PGC1α, and
PPARγ pathways. Impairments to these signalling pathways consequently effect the removal of
dysfunctional mitochondria, which has been suggested as contributing to the development of
neurodegeneration. Mitochondrial dysfunction prevention has become an attractive therapeutic
target, and there are several molecular pathways that can be pharmacologically targeted to remove
damaged mitochondria by inducing mitochondrial biogenesis or mitophagy, as well as increasing
the antioxidant capacity of the brain, in order to alleviate mitochondrial dysfunction and prevent the
development and progression of neurodegeneration in these disorders. Compounds such as natural
polyphenolic compounds, bioactive quinones, and Nrf2 activators have been reported in the literature
as novel therapeutic candidates capable of targeting defective mitochondrial pathways in order to
improve mitochondrial function and reduce the severity of neurodegeneration in these disorders.
Keywords: mitochondrial dysfunction; oxidative stress; neurodegeneration; Parkinson’s disease;
methylmalonic acidaemia; lysosomal storage disorders; mitochondrial biogenesis; mitophagy;
antioxidant defenses; therapeutics
1. Introduction
Neurodegeneration is characterised by progressive deterioration of the neuronal struc-
ture and function, leading to cognitive impairments and dementia [1], and current evidence
suggests that mitochondria have a fundamental role in the development of neurodegenera-
tion [2]. Mitochondria are ubiquitous intracellular organelles that are the sites of aerobic
metabolism, producing adenosine triphosphate (ATP), as well as being responsible for
other processes including apoptosis regulation, cellular calcium homeostasis, and the gen-
eration of free radicals [3]. Mitochondria are sensitive to minor changes in the cellular redox
status [4], therefore mitochondrial dysfunction can lead to several deleterious consequences
such as oxidative stress (OS), secondary excitotoxicity, and activation of the mitochondrial
permeability transition pore (mPTP). Progressive impairments to mitochondrial activity
have been suggested to have a critical role in the pathogenesis of a range of diseases, in-
cluding progressive neurodegenerative diseases, such as Parkinson’s disease, Alzheimer’s,
disease and Amyotrophic Lateral Sclerosis, and metabolic diseases, including methylmalonic
acidaemia, lysosomal storage disorders, and Friedreich’s ataxia [5] (Figure 1).
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mitochondrial permeability transition pore (mPTP). Progressive impairments to mito-
chondrial activity have been suggested to have a critical role in the pathogenesis of a range 
of diseases, including progressive neurodegenerative diseases, such as Parkinson’s dis-
ease, Alzheimer’s, disease and Amyotrophic Lateral Sclerosis, and metabolic diseases, in-
cluding methylmalonic acidaemia, lysosomal storage disorders, and Friedreich’s ataxia 
[5] (Figure 1).  
Oxidative and nitrosative stress-related mitochondrial dysfunction has become a 
main focus of the pathogenic mechanisms that result in neuronal loss and neurodegener-
ation [6,7]. OS, defined by an imbalance between the excessive production of reactive ox-
ygen species (ROS) and reactive nitrogen species (RNS) and a reduced cellular antioxidant 
capacity, can disrupt the normal function of cellular metabolic processes, leading to im-
pairments in redox and energy production [8–10]. The cell contains a number of antioxi-
dant defence mechanisms in order to neutralise ROS/RNS, including enzymatic antioxi-
dants such as glutathione peroxidase (GPx), catalase (CAT), and superoxide dismutase 
(SOD), and non-enzymatic antioxidants such as glutathione (GSH), α-tocopherol (vitamin 
E), ascorbic acid (vitamin C), and natural flavonoids [11,12]. However, OS occurs if the 
generation of these highly reactive molecules overwhelms the cellular antioxidant capac-
ity, therefore both enzymatic and non-enzymatic defences are no longer able to prevent 
ROS/RNS from causing oxidative damage to several cellular components, including li-
pids, protein, and DNA [13]. 
The central nervous system (CNS) depends on efficient mitochondrial function [14] 
in order to maintain neuronal integrity and survival [15]. Mitochondria are the major 
source of endogenous ROS produced as a by-product from mitochondrial respiration, 
therefore the CNS is a very susceptible target for the accumulation and damage induced 
by ROS [16]. Additionally, mitochondrial-associated molecular pathways are often com-
promised [17] in the pathophysiology of neurodegeneration, including proteins fre-
quently dysregulated in mitochondrial biogenesis [18] and mitophagy [19], consequently 
effecting the removal of dysfunctional mitochondria. Failure to remove defective mito-
chondria can cause cellular distress and damage [20], and has been suggested to be a cause 
of neuronal death leading to neurodegeneration (Figure 2) [17]. However, it is currently 
unknown whether oxidative damage and/or abnormal mitochondrial morphology occur 
early on in disease progression or whether they are caused by secondary manifestations 
of the disease pathophysiology [21]. 
 
Figure 1. Mitochondrial dysfunction can lead to several deleterious consequences, contributing to 
the development and progression of neurodegeneration in a range of diseases. Failure to remove 
dysfunctional mitochondria can have profound effects on the central nervous system, leading to 
Figure 1. Mitochondrial dysfunction can lead to several deleterious consequences, contributing to
the development and progression of neurodegeneration in a range of diseases. Failure to remove
dysfunctional mitochondria can have profound effects on the central nervous syste , leading to
cellular distress and damage, ultimately leading to neuronal death. Up arrows represent increases
and down arrows represent reductions (created using biorender.com, accessed on 17 June 2021).
MRC—mitochondrial respiratory chain; ROS—reactive oxygen species.
Oxidative and nitrosative stress-related mitochondrial dysfunction has become a
main focus of the pathogenic mechanisms that result in neuronal loss and neurodegen-
eration [6,7]. OS, defined by an imbalance between the excessive production of reactive
oxygen species (ROS) and reactive nitrogen species (RNS) and a reduced cellular antiox-
idant capacity, can disrupt the normal function of cellular metabolic processes, leading
to impairments in redox and energy production [8–10]. The cell contains a number of
antioxidant defence mechanisms in order to neutralise ROS/RNS, including enzymatic
antioxidants such as glutathione peroxidase (GPx), catalase (CAT), and superoxide dis-
mutase (SOD), and non-enzymatic antioxidants such as glutathione (GSH), α-tocopherol
(vitamin E), ascorbic acid (vitamin C), and natural flavonoids [11,12]. However, OS occurs
if the generation of these highly reactive molecules overwhelms the cellular antioxidant
capacity, therefore both enzymatic and non-enzymatic defences are no longer able to prevent
ROS/RNS from causing oxidative damage to several cellular components, including lipids,
protein, and DNA [13].
The central nervous system (CNS) depends on efficient mitochondrial function [14] in
order to maintain neuronal integrity and survival [15]. Mitochondria are the major source
of endogenous ROS produced as a by-product from mitochondrial respiration, therefore the
CNS is a very susceptible target for the accumulation and damage induced by ROS [16].
Additionally, mitochondrial-associated molecular pathways are often compromised [17] in
the pathophysiology of neurodegeneration, including proteins frequently dysregulated in
mitochondrial biogenesis [18] and mitophagy [19], consequently effecting the removal of
dysfunctional mitochondria. Failure to remove defective mitochondria can cause cellular
distress and damage [20], and has been suggested to be a cause of neuronal death leading
to neurodegeneration (Figure 2) [17]. However, it is currently unknown whether oxidative
damage and/or abnormal mitochondrial morphology occur early on in disease progression
or whether they are caused by secondary manifestations of the disease pathophysiology [21].
New evidence has revealed that mitochondrial-targeted therapies represent important
novel therapeutic candidates for restoration of the mitochondrial function by ameliorating
OS and mitochondrial dysfunction in order to maintain neuronal cell integrity and function
in disorders that involve neurodevelopment disruptions, including Parkinson’s disease,
methylmalonic acidaemia, and lysosomal storage disorders [22]. These are highly prevalent
disorders and mitochondrial dysfunction is a common theme among these three inheritable
Int. J. Mol. Sci. 2021, 22, 11444 3 of 35
and non-communicable disorders [23]. Therefore, targeting dysfunctional mitochondria
could be a potential therapeutic target in order to treat and/or prevent neurodegeneration
in these disorders. Several compounds have been identified in the literature as being
capable of targeting defective mitochondrial pathways in order to enhance mitochondrial
function and reduce the consequences of OS, for example natural polyphenolic compounds,
such as resveratrol and curcumin, capable of inducing mitochondrial biogenesis [24];
widely used FDA-approved drugs, such as dimethyl fumarate (DMF) [25], known to
successfully target impaired mitophagy, and the Nrf2-antioxidant responsive element
(Nrf2-ARE) pathway, an endogenous antioxidant defence system; and novel therapeutics,
such as deubiquitinases (DUBs), modulating mitochondrial clearance via mitophagy [26].
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son’s disease, methylmalonic acidaemia, and lysosomal storage disorders [22]. These are 
highly prevalent disorders and mitochondrial dysfunction is a common theme among 
these three inheritable and non-communicable disorders [23]. Therefore, targeting dys-
functional mitochondria could be a potential therapeutic target in order to treat and/or 
prevent neurodegeneration in these disorders. Several compounds have been identified 
in the literature as being capable of targeting defective mitochondrial pathways in order 
to enhance mitochondrial function and reduce the consequences of OS, for example natu-
ral polyphenolic compounds, such as resveratrol and curcumin, capable of inducing mi-
tochondrial biogenesis [24]; widely used FDA-approved drugs, such as dimethyl 
fumarate (DMF) [25], known to successfully target impaired mitophagy, and the Nrf2-
antioxidant responsive element (Nrf2-ARE) pathway, an endogenous antioxidant defence 
system; and novel therapeutics, such as deubiquitinases (DUBs), modulating mitochon-
drial clearance via mitophagy [26].  
 
Figure 2. Putative common mechanisms leading to mitochondrial dysfunction and neurodegenera-
tion in Parkinson’s disease, methylmalonic acidaemia, and lysosomal storage disorders. α-Synu-
clein, PINK1, and parkin are proteins frequently mutated in neurodegenerative disorders causing 
abnormal mitochondrial dynamics, including altered mitochondrial morphology, impaired MRC 
function and mitophagy, misfolded proteins, and reduced ΔΨm. These consequences result in mi-
tochondrial dysfunction, triggering neuronal dysfunction that leads to neurodegeneration and neu-
ronal death (created using biorender.com). PINK1—TEN-induced kinase 1; MRC—mitochondrial 
Figure 2. Putative co mon mechanisms leading to mitochondrial dysfunction and neurodegenera-
tion in Parkinson’s is , i acidaemia, and lysosomal storage disorders. α-Synuclein,
PINK1, and parkin are prot ins fr quently mu ated in n urodegenerative disord rs causing abnormal
mitochondrial dynamics, including altered mitochondrial morphology, impaired MRC function and
mitophagy, misfolded proteins, and reduced ∆Ψm. These consequences result in mitochondrial dys-
function, triggering neuronal dysfunction that leads to neurodegeneration and neuronal death (created
using biorender.com). PINK1—TEN-induced kinase 1; MRC—mitochondrial respiratory chain; MPTP—
mitochondrial permeability transition pore; ∆Ψm—mitochondrial membrane potential; ATP—adenosine
triphosphate; ROS—reactive oxygen species; OMM—outer mitochondrial membrane.
The aim of this review will be to focus on common mechanisms leading to mito-
chondrial dysfunction and neurodegeneration in diseases representing non-metabolic
neurodegenerative disorders, such as Parkinson’s disease, together with examples of
rare metabolic diseases, such as methylmalonic acidaemia, together with more common
metabolic diseases as exemplified by lysosomal storage disorders. This review will then
discuss the various mitochondrial-associated molecular pathways that are frequently dys-
regulated in these disorders, including the parkin/PINK1, Nrf2, PGC1α, and PPARγ
pathways, as well as outlining potential therapeutic strategies in order to alleviate the
mitochondrial dysfunction and OS associated with neurodegeneration in these metabolic
and non-metabolic disorders.
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2. Mitochondrial Dysfunction and Oxidative Stress: Key Events in Neurodegeneration
Neurodegenerative and inherited metabolic diseases are a heterogenous group of
disorders that can be inherited in an autosomal recessive pattern and be associated with
neurological impairment, characterised by progressive loss of neurons in regions of the
brain that compromise nervous system function [27,28]. The majority of disorders involving
the CNS result in major neurodevelopment disruptions producing a wide variety of clinical
manifestations, ranging from mild neurological signs, such as learning difficulties, to
severe global encephalopathies [29]. Recent evidence has demonstrated that mitochondrial
dysfunction and oxidative stress are important aetiological factors in the development and
progression of neurodegeneration, resulting in alterations in the cellular redox state and
injury to nervous system structural components, eventually leading to neuronal death.
Evidence of OS and secondary mitochondrial dysfunction have been hypothesised
as key events triggering neurodegeneration (Figure 3) [30,31]. Firstly, OS-induced im-
pairments to mitochondrial function contribute to cellular energy failure as a result of
the overproduction of free radicals generated as part of the pathogenesis of disease [9].
ROS-induced mitochondrial impairments include mitochondrial DNA (mtDNA) damage
leading to mutations in the mitochondrial genome, direct impairment to complexes in the
mitochondrial respiratory chain (MRC), changes in mitochondrial membrane permeability
and structure, and reduced efficiency of the mitochondrial defence systems [31]. Free
radicals are produced under normal physiological conditions as the mitochondria contain
numerous electron carriers producing ROS [6]; however, free radical-induced oxidative
damage caused by the simultaneous accumulation of ROS/RNS and inefficient ROS pro-
tection exacerbates mitochondrial dysfunction. Moreover, other factors responsible for dys-
functional mitochondria include mitochondrial matrix enzymes, such as α-ketoglutarate
dehydrogenase and pyruvate dehydrogenase, which are important ROS generators, and
tricarboxylic acid (TCA) cycle enzymes, such as aconitase and α-ketoglutarate dehydro-
genase, which are susceptible to ROS-mediated damage [32,33]. In addition, the accu-
mulation of toxic molecules and by-products characteristic of certain neurodegenerative
and metabolic diseases also contribute to mitochondrial dysfunction [30]. These changes
are implicated in the pathogenesis of these disorders, and therefore facilitate neuronal
dysfunction, triggering neurodegeneration [31].
The CNS depends on efficient mitochondria in order to function effectively, as the
brain and neurons have high metabolic demands [6,14]. Under physiological conditions,
ROS are essential for the development and function of neurons in small quantities, and the
brain is able to effectively regulate oxygen consumption and redox capacity [34]. However,
the brain has a high oxygen consumption rate; low antioxidant defence mechanisms [15],
comprising of low levels of GSH and GPx and almost no CAT [6]; and a high concentration
of polyunsaturated fatty acids, which are prone to oxidation [15], therefore meaning that
the brain is very susceptible to oxidative injury. It is well-known that ROS accumulation
increases the susceptibility of the cerebral tissue to damage, and free radicals are believed to
trigger a cascade of molecular events resulting in altered brain morphology and increases in
blood–brain barrier (BBB) permeability [34]. These alterations activate neuroinflammatory
processes, favouring cellular injury and death.
Furthermore, neurons are particularly more sensitive to the accumulation and damage
induced by ROS, as neurons rely on mitochondria due to their inadequate glycolytic
capacity, which means that they have a high rate of mitochondrial activity in order to fulfil
their energetic requirements via oxidative phosphorylation (OXPHOS) [13,27]. This results
in disruption of neuronal homeostasis, as mitochondria are the major source of endogenous
ROS produced as a by-product of OXPHOS [16]. Therefore, OS-induced alterations in
mitochondrial dynamics and reduced cellular energy status, as well as decreased neuronal
plasticity, eventually contribute to the development of neurodegeneration [6].
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Figure 3. Mitochondrial dysfunction and oxidative stress are key events triggering neurodegeneration. Mitochondria are 
vulnerable targets for oxidative stress. ROS accumulation from mitochondria and endogenous and exogenous sources can 
cause oxidative damage to cellular components as they go unchallenged from diminished antioxidant defence systems. A 
chronic oxidation environment causes dysregulation of the critical pathways causing a lower gene expression of the anti-
oxidant enzymes and transcription factors involved in mitochondria-dependent apoptosis. A combination of these factors 
results in neuronal apoptosis and senescence, triggering neurodegeneration (created using biorender.com). ROS—reactive 
oxygen species; OXPHOS—oxidative phosphorylation; mtDNA—mitochondrial DNA; BBB—blood−brain barrier. 
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brain and neurons have high metabolic demands [6,14]. Under physiological conditions, 
ROS are essential for the development and function of neurons in small quantities, and 
the brain is able to effectively regulate oxygen consumption and redox capacity [34]. How-
ever, the brain has a high oxygen consumption rate; low antioxidant defence mechanisms 
[15], comprising of low levels of GSH and GPx and almost no CAT [6]; and a high concen-
tration of polyunsaturated fatty acids, which are prone to oxidation [15], therefore mean-
ing that the brain is very susceptible to oxidative injury. It is well-known that ROS accu-
mulation increases the susceptibility of the cerebral tissue to damage, and free radicals are 
believed to trigger a cascade of molecular events resulting in altered brain morphology 
and increases in blood–brain barrier (BBB) permeability [34]. These alterations activate 
neuroinflammatory processes, favouring cellular injury and death.  
Furthermore, neurons are particularly more sensitive to the accumulation and dam-
age induced by ROS, as neurons rely on mitochondria due to their inadequate glycolytic 
capacity, which means that they have a high rate of mitochondrial activity in order to fulfil 
their energetic requirements via oxidative phosphorylation (OXPHOS) [13,27]. This re-
sults in disruption of neuronal homeostasis, as mitochondria are the major source of en-
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antioxida t enzymes and transcription factors involved in mitochondria-dependent apoptosis. A combination of these
factors results in neuronal apoptosis and senescence, triggering neurodegeneration (created using biorender.com). ROS—
reactive oxygen species; OXPHOS—oxidative phosphorylation; mtDNA—mitochondrial DNA; BBB—blood−brain barrier.
3. Altered Signaling Pathways Leading to Mit chondrial Dysfunctio in Neurological Di eas
3.1. Protein F nction in Healt
3.1.1. Parkin and PINK1
Parkin and phosphatase and tensin homolog (PTEN)-induced kinase 1 (PINK1) are
mitochondrial quality control regulators, stimulating the removal of damaged mitochon-
dria [35]. Parkin is widely expressed in various tissues, including the brain, where this
protein is equally expressed in several brain sub-regions and is most abundant in the
substantia nigra [36]. Parkin functions as a cytosolic E3 ubiquitin ligase, ubiquitinating
proteins targeted for signalling or proteasomal degradation [35]. Moreover, despite parkin
being localised to the cytosol, it is an important protein for efficient mitochondrial function,
as parkin recruitment from the cytosol to depolarised mitochondria is crucial for the selec-
tive autophagic removal (mitophagy) of damaged mitochondria, therefore maintaining a
functional mitochondrial pool [35,37].
PINK1 is a mitochondrial serine/threonine kinase that is essential for the maintenance
of mitochondrial homeostasis and has an important role within mitophagy. PINK1 exerts a
neuroprotective effect and functions to protect dopaminergic neurons against OS-induced
apoptosis, as it is capable of inhibiting ROS production by functioning as a mitochondrial
serine/threonine (Ser/Thr) protein kinase [8,38,39]. The kinase activity of PINK1 has an
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essential role in the induction of mitophagy, as damaged mitochondria are removed following
the activation of PINK1 and parkin [40]. Under healthy, physiological conditions, PINK1
accumulates at the outer mitochondrial membrane (OMM) of the damaged mitochondria in
response to a reduction in mitochondrial membrane potential (∆Ψm) or misfolded protein
accumulation, therefore initiating the translocation of parkin to the mitochondria. Once sta-
bilised at the OMM, PINK1 phosphorylates ubiquitin at Ser65 in order to activate the ubiquitin
ligase activity of parkin, and removes defective mitochondria via selective autophagy.
3.1.2. Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-Alpha (PGC1α)
PGC1α, a transcriptional coactivator, is well-known as the master regulator of mito-
chondrial biogenesis and function, and is highly expressed in tissues with high energy
demands and mitochondria-rich cells, such as neurons [24,41]. PGC1α regulates mito-
chondrial biogenesis by making mitochondria more bioenergetically competent, favouring
enhanced mitochondrial biogenesis [42]. Mitochondrial mass is controlled via a dynamic
equilibrium between degradation and biogenesis, and mitochondrial biogenesis is primar-
ily regulated via the activation of PGC1α, leading to the activation of other transcription
factors, including nuclear respiratory factors (NRF-1 and -2) and PPARs [24]. PGC1α inter-
acts with NRF-1 and NRF-2 to stimulate their transcriptional activity via protein–protein
interactions, resulting in an increased expression of mitochondrial transcription factor A
(TFAM), subsequently stimulating mitochondrial biogenesis via the increased expression
of intracellular ATP concentrations and OXPHOS [42]. Moreover, the expression of cellular
antioxidant defences, including manganese superoxide dismutase (MnSOD/SOD2) and CAT,
are upregulated via PGC1α in order to protect the cell from excessive mitochondrial ROS gen-
eration and dysfunction, and to prevent mitochondrial failure-associated cell death. PGC1α
expression and activity are also activated via ROS/RNS. Furthermore, PGC1α modulates
the key pathways required for neuronal function, and PGC1α activity in neurons may be
involved in the regulation of neuronal mitochondrial density, as well as the cellular response
to OS in order to reduce overall tissue damage [22,43]. Therefore, PGC1α may represent a key
target for increasing healthy and functional mitochondrial pools [44].
3.1.3. Peroxisome Proliferator-Activated Receptor Gamma (PPARγ)
PPARγ is a member of the peroxisome proliferator-activated receptors (PPARs), which
are a nuclear receptor superfamily of ligand-inducible transcription factors compromising
of three subtypes; PPARα, PPARγ, and PPARβ/δ [45]. The PPAR family has a major role
in the regulation of energy homeostasis and metabolic function, and have distinctive tissue
expression, however PPARγ is highly expressed in dopaminergic cells in the basal ganglia as
well as in the midbrain [45,46]. The primary function of PPARγ is to regulate the expression
of the gene networks involved in metabolism, metabolic homeostasis, and inflammation [47].
In addition, PPARγ activation is involved in cellular differentiation and proliferation, as
well as having anti-apoptotic and anti-oxidant effects [46]. It is a key positive regulator
of mitochondrial biogenesis and is able to restore the cellular redox environment via the
activation of the PPARγ coactivator, PGC1α [44]. It has been demonstrated that mitochondrial
biogenesis is mediated via PPARγ stimulation via the induction of PGC1α [48]. Studies
have demonstrated that PPAR dysfunction is associated with CNS dysfunction and therefore
demonstrates the key role that PPARγ has in maintaining nervous system integrity [46].
3.1.4. Nuclear Factor Erythroid 2-Related Factor (Nrf2)
Nrf2, referred to as the master regulator of antioxidant detoxification and cell defence
gene expression, is a transcription factor that plays a crucial role in protecting the cell
against environmental stressors through a promoter sequence, known as the antioxidant-
responsive element (ARE) [49]. The Nrf2-ARE pathway activates numerous cytoprotective
genes including antioxidants and several transcription factors involved in mitochondrial
biogenesis [50]. Mitochondrial biogenesis is thought to be induced via the translocation
of Nrf2 to the nucleus where Nrf2 binds to the NRF1 promoter of ARE, activating TFAM,
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which directly drives mtDNA replication [51]. In addition, Nrf2 has important roles
in cell survival, energy metabolism, and the anti-inflammatory response [49]. Under
physiological conditions, Nrf2 is found in the cytosol where it is bound to Kelch-like
ECH-associated protein 1 (Keap1), until it is activated via oxidants and electrophiles,
resulting in the migration and accumulation of Nrf2 in the nucleus. Thus, increasing the
expression of various antioxidants within the cell, including SOD1, GSH, and NADH
quinone oxidoreductase (NQO1), therefore protecting the cell from OS events [38].
The signalling molecules involved in the maintenance of a healthy mitochondrial pool
in health are outlined in Figure 4.
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Figure 4. Signaling pathways involved in maintaining a healthy mitochondrial pool in health. PINK1 and parkin have 
protective roles in neurons and have essential roles in mitophagy. PINK1 accumulates at the outer mitochondrial mem-
brane of damaged mitochondria, initiating the translocation of parkin from the cytosol to mitochondria, activating parkin 
and selecting damaged mitochondria for removal via mitophagy. The activation of PGC1α regulates mitochondrial bio-
genesis, leading to upregulation of several transcription factors and cellular antioxidants. PGC1α is directly regulated via 
AMPK phosphorylation and SIRT1-mediated deacetylation which induces mitochondrial biogenesis. PPARγ is a positive 
regulator of mitochondrial biogenesis and interaction between PPARγ and PGC1α allows PGC1α to interact with several 
transcription factors and restore the cellular redox environment by regulating the expression of cellular antioxidants, in-
cluding MnSOD and CAT. Nrf2 is bound to Keap1 in the cytosol and migrates and accumulates in the nucleus upon 
activation by antioxidants and electrophiles. Nrf2 binds to the promoter sequence of the ARE where it upregulates the 
expression of several cellular antioxidants and transcription factors involved in mitochondrial biogenesis [Created using 
biorender.com]. PINK1—PTEN-induced kinase 1; ROS—reactive oxygen species; ΔΨm—mitochondrial membrane po-
tential; ATP—adenosine triphosphate; Keap1—Kelch-like ECH-associated protein 1; Nrf2—nuclear factor erythroid 2-re-
lated factor; PGC1α—peroxisome proliferator-activated receptor gamma coactivator 1-alpha; AMPK—AMP-dependent 
kinase; SIRT1—silent mating type information regulation 2 homolog 1; ARE—antioxidant-responsive element; TF—tran-
scription factor; SOD—superoxide dismutase; GSH—glutathione; NQO1—NADH quinone oxidoreductase; MnSOD—
manganese superoxide dismutase; CAT—catalase; PPARγ—peroxisome proliferator-activated receptor gamma. 
3.2. Non-Communicable Diseases 
Non-communicable diseases (NCDs) are defined as chronic conditions that are non-
infectious and non-transmissible, with the most common NCDs being related to the car-
diovascular and nervous system [52]. Mitochondrial dysfunction, OS, and inflammation 
are common associations with NCDs and are suggestive of playing a critical role in disease 
pathogenesis of these disorders. Several lines of evidence have demonstrated that im-
paired mitochondrial function and dynamics are causative factors in several neurodegen-
erative diseases, and altered molecular pathways affecting mitochondrial function in 
these disorders are believed to be major risk factors in disease progression, as regulation 
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mitochondria for removal via mitophagy. The activation of PGC1α regulates mitochondrial biogenesis, leading to upregulation
of several transcription factors nd cellular ntioxidants. PGC1α is directly regulated via AMPK phosphorylation nd SIRT1-
mediated deacetylation which induces mitochondrial biogenesis. PPARγ is a positive regulator of mitochondrial biogenesis
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3.2. Non-Communicable Diseases
Non-communicable diseases (NCDs) are d f n d as chronic conditions that are non-
infectious and non-transmissible, with the most common NCDs being related to the car-
diovascular and nervous system [52]. Mitochondrial dysfunction, OS, and inflammation
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are common associations with NCDs and are suggestive of playing a critical role in disease
pathogenesis of these disorders. Several lines of evidence have demonstrated that impaired
mitochondrial function and dynamics are causative factors in several neurodegenerative
diseases, and altered molecular pathways affecting mitochondrial function in these disorders
are believed to be major risk factors in disease progression, as regulation of mitochondrial
function is essential for neuronal signalling, plasticity, and transmitter release [50,53].
3.2.1. Parkinson’s Disease
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder
after Alzheimer’s disease, and the most common movement disorder amongst the current
population [54]. The clinical manifestations of the disease are characterised by clinical
motor symptoms, including bradykinesia, resting tremor, rigidity, and postural instability,
as well as non-motor symptoms, including cognitive deficits, depression, and autonomic
and sensory dysfunction, eventually leading to near total immobility [54,55]. PD is charac-
terised by two main pathological features, loss of dopaminergic neurons in the substantia
nigra pars compacta (SNpc) of the midbrain and the development of intracytoplasmic inclu-
sions, known as Lewy bodies, predominantly containing accumulated fibrillar α-synuclein
in affected regions of the brain. These neuropathologies are thought to underlie the
characteristic motor phenotype of PD patients, contributing to the development of neurode-
generation [53]. Although the aetiology of PD has not yet been fully elucidated, several
human studies and animal models of PD have demonstrated that abnormal mitochondrial
function and protein accumulation are key contributors in the pathogenesis of both spo-
radic and familial forms of PD, as well as OS, which contributes to the development of the
two main pathogenic events [55]. Moreover, PD is frequently attributable to mutations in
genes encoding for α-synuclein, parkin, and PINK1, and therefore can provide insights
into the altered molecular pathways underlying neurodegeneration in PD.
PINK1/Parkin Mutations and Mitochondrial Dysfunction
Several lines of evidence have demonstrated that mitochondrial dysfunction has a
primary role in the pathogenesis of PD, as many of the pathogenic mutations associated with
PD are directly related to mitochondrial dysfunction (Figure 5) [22,35]. Parkin mutations
are the most common cause of autosomal recessive PD, and are also the most sensitive to
oxidative damage, and PINK1 mutations are the second most frequent cause of autosomal
recessive early-onset PD [56]. In order to ensure cell survival, healthy neurons remove
dysfunctional mitochondria efficiently via mitophagy as a quality control mechanism [37].
However, mutations resulting in a loss of function of both parkin and PINK1 result in the
death of many cell types, including dopaminergic neurons, whose dysfunction is mainly
responsible for the classical motor deficits of PD [57]. This is because these neurons have
a reduced ability to remove dysfunctional mitochondria as a consequence of mutations in
parkin and PINK1, preventing the recruitment of parkin to the mitochondria and therefore
interfering with mitophagy efficiency [37]. This results in an accumulation of damaged
mitochondria, making these cells vulnerable targets for OS and death [58]. Additionally, mi-
tochondrial ROS production is significantly increased as a result of dysfunctional PINK1 and
parkin [59]. A reduced ability to cleave PINK1 between Ala-103 and Phe-104 in order to gen-
erate the 53 kDA PINK1 protein, augments mitochondrial and cytoplasmic ROS production,
in addition to significantly reducing basal ∆Ψm [60]. Moreover, parkin has been recognised
to conjugate both phosphorylated and unphosphorylated ubiquitin to the substrate located
on the depolarized mitochondria [60]. However, if this mechanism is dysfunctional, an
accumulation of abnormal mitochondria and an overproduction of ROS can occur.
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impairs mitochondrial biogenesis via direct binding to the PGC1α promoter, downregulating the 
PGC1α expression. Both parkin/PINK1 mutations and α-synuclein accumulation cause reduced 
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OS—oxidative stress. 
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KO Drosophila as a result of these proteins operating in the same genetic pathway in order 
to maintain functional mitochondria [63]. Moreover, altered mitochondrial morphology 
and muscle degeneration in PINK1 KO Drosophila were salvaged via parkin overexpres-
sion, but this was not observed with PINK1 overexpression in parkin KO Drosophila, indi-
cating that PINK1 is an upstream regulator of parkin function [56]. Similar to Drosophila 
models, PINK1 KO mice exhibit MRC defects within the striatum. A study carried out by 
Gispert et al. (2009) generated PINK1 deficient mice and identified characteristics similar 
to PD development in humans, including dopaminergic synapse dysfunction and protu-
berant mitochondrial dysfunction [61]. The study observed that PINK1 KO mice had im-
paired mitochondrial electron transport chain (ETC) complex I + III + IV activity within 
the brain, as well as reductions in ΔΨm and ATP generation, resulting in mitochondrial 
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Studies in Drosophila melanogaster first identified the role of parkin and PINK1 in the
maintenance of the mitochondria [37]. PINK1 knockout (KO) Drosophila were found to
have defects in mitochondrial morphology, including fragmented mitochondrial cristae,
hypersensitivity to OS, MRC defects, and degeneration of dopaminergic neurons, which
are mechanisms that have been suggested as contributing early on in the pathogenesis of
PD [56,61,62]. In parkin KO Drosophila, the same phenotype was observed as in the PINK1
KO Drosophila as a result of these proteins operating in the same genetic pathway in order
to maintain functional mitochondria [63]. Moreover, altered mitochondrial morphology
and muscle degeneration in PINK1 KO Drosophila were salvaged via parkin overexpression,
but this was not observed with PINK1 overexpression in parkin KO Drosophila, indicating
that PINK1 is an upstream regulator of parkin function [56]. Similar to Drosophila models,
PINK1 KO mice exhibit MRC defects within the striatum. A study carried out by Gispert
et al. (2009) generated PINK1 deficient mice and identified characteristics similar to PD
development in humans, including dopaminergic synapse dysfunction and protuberant
mitochondrial dysfunction [61]. The study observed that PINK1 KO mice had impaired
mitochondrial electron transport chain (ETC) complex I + III + IV activity within the brain,
as well as reductions in ∆Ψm and ATP generation, resulting in mitochondrial bioenergetic
dysfunction. A reduction in ∆Ψm below a certain threshold is often caused by uncouplers
or OS, and is required for the activation of mitophagy, favouring the accumulation of
PINK1 at the OMM [64,65]. However, PINK1 processing is incomplete in damaged mito-
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chondria as a consequence of reduced ∆Ψm. Consequently, a deficiency in PINK1 becomes
more apparent under conditions of cellular stress, which may explain why dopaminergic
neurons in PINK1-associated PD have an increased susceptibility to death, as these neurons
are particularly vulnerable to increased levels of OS as a result of dopamine metabolism,
and PINK1 KO causes increased ROS generation [38,61]. Dopamine and its oxidation
by-products may contribute to increased ROS generation and mitochondrial respiration
inhibition in PD, specifically the inactivation of mitochondrial electron transport chain
(ETC) complex I, as these metabolites have been found to interact with the OXPHOS sys-
tem [66–68]. In isolated brain mitochondria from a rat model of PD, dopamine was found
to inhibit mitochondrial respiration in a dose-dependent manner, as well as via interaction
with mitochondrial toxins. PD patient studies have provided evidence for a 35% decrease
in complex I activity, suggesting that dopamine may be a potential contributor to OS and
mitochondrial dysfunction within dopaminergic neurons, leading to neuronal damage and
degeneration. However, without stress conditions, PINK1 KO mice neurons also show
reduced ATP levels, and isolated mitochondria from PINK1 KO cerebral tissue demonstrate
a significant and progressive reduction in ∆Ψm, although this may be associated with age.
Mitochondrial abnormalities in the dopaminergic neurons of PD patients and dopamine
neuronal cultures were investigated by Chung et al. (2016), who identified mitochondrial
defects and protein accumulation in parkin and PINK1 induced pluripotent stem cell (iPSC)-
derived midbrain neuronal populations [58]. These neuronal populations revealed a consid-
erable accumulation of abnormal mitochondria, in comparison with control iPSCs, which
comprised of a smaller fraction of abnormal mitochondria after 75 days of differentiation.
The abnormal mitochondria were also observed as being larger in size compared with the
control neurons. This suggests that mutations in parkin and PINK1 are capable of triggering
alterations in mitochondrial homeostasis, initiating multiple cellular pathogenic modifica-
tions. Another study with parkin mutant iPSC neurons showed increased OS and reduced
GSH levels, accompanied by Nrf2 pathway activation [69]. Increases in OS were supported
in post-mortem PD brains where increased levels of 4-hydroxyl-2-nonenal (HNE), a by-
product of lipid peroxidation, and 8-hydroxy-guanosine and 8-hydroxy-deoxyguanosine,
by-products of DNA and RNA oxidation, respectively, were identified [70]. Post-mortem PD
brains were also found to have an increased expression of Nrf2 pathway proteins, including
Nrf2 and NQO1, suggesting that the Nrf2 pathway is activated in iPSC-derived neurons in
order to protect neurons from further oxidative damage. The Nrf2-ARE pathway is often
downregulated in several neurodegenerative disorders, suggesting that parkin mutations
are capable of impairing the Nrf2 antioxidant pathway [38]. Nevertheless, the cell is able to
compensate by upregulating antioxidant protective pathways, and therefore provides an
important therapeutic target.
α-Synuclein and Mitochondrial Dysfunction
α-synuclein aggregation and accumulation is strongly associated with several neu-
rodegenerative diseases, including PD, dementia with Lewy bodies (DLB), and multiple
system atrophy (MAS). Evidence of α-synuclein aggregates have been recognised in post-
mortem PD brains to accumulate within mitochondria, despite its predominant localisation
to the cytosol [71,72]. Overactivation of autophagy is a potential link between mitochon-
drial dysfunction and α-synuclein accumulation [73], and intracellular accumulation has
been shown to be capable of inducing OS and increasing ROS levels, as well as inducing
mitochondrial fragmentation [74]. Although the mechanisms are not yet fully understood,
evidence has shown that α-synuclein has direct effects on mitochondrial morphology due
to mutations encoding α-synuclein increasing mitochondrial fragmentation as well as
affecting mitochondrial biogenesis via the regulation of PGC1α [38,75]. A study using
human dopaminergic neurons with overexpressed mutant A53T α-synuclein has provided
evidence that basal and toxin-induced oxidative/nitrosative stress results in an inhibition
of the MEF2C-PGC1α transcriptional network [75]. Myocyte enhancer factor 2 (MEF2C)
is a transcription factor that binds to the PGC1α promoter activating it, and evidence has
shown that the inhibition of this network contributes to mitochondrial dysfunction and
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apoptotic cell death in PD [75,76]. Moreover, this toxic protein has been found to interact
with mitochondrial membranes, including in neuronal synapses, and has been associated
with impaired complex I-dependent respiration and reduced ∆Ψm, therefore impacting
energy production and mitochondrial ROS production [37]. Recent evidence has identified
an interaction between α-synuclein and MRC complex I, resulting in reduced mitochondrial
activity and exacerbated ROS production [77]. The relevant molecular target has been found
to be the N-terminal domain of α-synuclein, which targets the aggregated protein towards
MRC complex I. It has also been reported that soluble α-synuclein is capable of directly in-
teracting with mitochondria-associated endoplasmic reticulum membranes (MAM), which
can cause an overexpression of the proteins that alter mitochondrial morphology and cause
mitochondrial fragmentation in cell models of PD [78]. Additionally, α-synuclein has been
found to bind to OMM proteins, including the voltage-dependent anion-selective channel 1
(VDAC1), which has been implicated as a factor contributing to mitochondrial dysfunction
in sporadic PD [35]. Levels of VDAC1 in nigral neurons of patients with sporadic PD were
found to be reduced as a consequence of α-synuclein aggregation.
Thereby, parkin, PINK1, and α-synuclein represent important therapeutic targets in
order to alleviate mitochondrial dysfunction and bioenergetic deficits, leading to neurode-
generation in both sporadic and familial PD.
3.3. Inherited Metabolic Disorders
Inherited metabolic disorders (IMDs) are a large group of single gene disorders af-
fecting several features of cellular metabolism [79]. These disorders are traditionally
well-known as enzymopathies due to disturbances in specific pathways leading to the
accumulation of toxic metabolites or intermediate products and/or reduced synthesis of an
essential metabolite. The majority of IMDs involve the CNS, resulting in major neurodevel-
opmental disruptions during the first stages of life, as a consequence of the impairment in
cellular function due to the presence of toxic metabolites and intermediates that accumulate
in these disorders [80]. In the brain, these metabolites can behave as neurotransmitters or
stimulate biological pathways, which can result in neuronal dysfunction and ultimately
neurodegeneration. Several studies from patients and animal models have provided evi-
dence to demonstrate that metabolic alterations in mitochondria and energy dysfunction
may play a vital role in the pathophysiology of neurological disease in IMDs, and that
bioenergetic disruption is a crucial biochemical event leading to neurodegeneration in
metabolic disease [81].
3.3.1. Methylmalonic Acidaemia
Methylmalonic acidaemia (MMAemia), the most common organic acidaemia, is
an autosomal recessive IMD and is a severe, multi-system disease of abnormal organic
acid metabolism [82]. MMAemia is caused by deficiency of the mitochondrial enzyme
L-methylmalonyl-CoA mutase (MMUT) activity, which is essential for the degradation
of amino acids such as valine, isoleucine, and methionine and lipids, or by defects in
the uptake, transport, or synthesis of the MMUT cofactor, 5′-deoxyadenosylcobalamin
(AdoCbl) (Figure 6) [83,84]. Defects in the activity of MMUT increase the concentration
of methylmalonic acid (MMA), the primary metabolite accumulating in MMAemia, in
patient tissues and body fluids, including urine and cerebrospinal fluid (CSF). Additionally,
the accumulation of secondary metabolites, including 2-methylcitrate (MCA), malonic
acid (MA), propionate, and 3-hydroxypropionate, are also detected and are mitochondrial
toxins capable of inducing excitotoxicity and OS [84,85]. MMAemia has a wide clinical
spectrum, with the disease manifestations ranging from the fatal neonatal period to adult-
hood. The severe, early-onset form of the disease typically presents in neonates with lactic
acidosis, hyperammonaemia, lethargy, failure to thrive, and neurological defects, including
developmental delay, hypotonia, convulsions, metabolic stroke (acute and chronic basal
ganglia involvement), and coma [82]. Long-term complications, such as renal failure and
neurological diseases, are frequently observed in MMAemia patients.
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Mitochondrial Dysfunction and Oxidative Stress Contribute to Neurodegeneration in
Methylmalonic Acidaemia
Several animal MMAemia models and patient studies have demonstrated that mito-
chondrial dysfunction is an important contributor to the development of neurodegeneration
i MMAemia [81]. In patie t studi s, this ha been supported by elevated levels of lactic
acid—a ndicator f impaired MRC function—in the CSF and globus pallidus of the brain,
as well as elevated levels of the TCA cycl intermediate, citric acid, in the blood (Figure 7).
These elevated biomarkers are s ggestive of an impairment of mitochondrial metabolism,
such as mitochondrial abnormalities a d MRC enzyme complex inhibition, ultimately
leading to neuronal loss. In a study undertaken by Brusque et al. (2002), millimolar MMA
concentrations consistent with those reported in MMAemia patients were found to inhibit
the MRC in the cerebral cortex of young rats [85]. The MRC complex I activity was sig-
nificantly inhibited by the presence of MMA, which was found to be a weak inhibitor of
complex II (succinate dehydrogenase) activity, suggesting that MMA may be considered
as a neurotoxin. Interestingly, inhibition of complex I activity has also been observed in
the basal ganglia of PD patients. Therefore, it may be assumed that inhibition of the MRC
complexes by MMA is perhaps very destructive to the brain, as OXPHOS is a highly active
system in the cerebral tissue [85,86].
Other studies have suggested that MMA may induce secondary excitotoxicity and OS,
which are well-established mechanisms involved in neuronal damage [87]. Experimental
evidence has found several OXPHOS defects in MMAemia patient and MMUT KO mice
models, resulting in perturbations in antioxidant defence systems, which, as a consequence,
cause oxidative damage, leading to MMA-induced deficient energy metabolism. Studies
with MMAemia-patient fibroblasts have identified an increased expression of multiple
proteins related to OS and apoptosis, including cytochrome c and MnSOD, as well as
significant increases in intracellular ROS levels [85]. Moreover, Atkuri et al. (2009) found
that MMAemia patients expressed lower levels of GSH in multiple immune cells compared
Int. J. Mol. Sci. 2021, 22, 11444 13 of 35
with healthy controls [88]. In cultured neurons, MMA accumulation was also found to
reduce the ATP/ADP ratio and cause mitochondrial membrane depolarisation and ion gra-
dient failure, leading to necrotic and apoptotic cell death [89–91]. Additionally, secondary
metabolites of MMA, such as MCA, MA, and propionyl-CoA, have been demonstrated to
also inhibit the activity of the MRC and TCA cycle [87]. It has been suggested that neuronal
damage in MMAemia is not caused by MMA alone, but by the synergistic contribution of al-
ternate propionyl-CoA oxidation metabolites. These secondary metabolites are considered
as neurotoxic agents, as they have been demonstrated to be capable of impairing OXPHOS
via pyruvate dehydrogenase complex inhibition and inducing hyperammonaemia via
N-acetylglutamate synthetase inhibition.
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Figure 7. Mechanisms resulting in mitochondrial dysfunction and the development of neurodegeneration due to defi-
cient L-methylmalonyl-CoA mutase activity and the accumulation of methylmalonic acid and secondary metabolites in
methylmalonic acidaemia. Mitochondrial accumulation of these toxic organic acids leads to consequences that affect the
mitochondrial structure and function such as reduced ∆Ψm and ATP; impaired MRC function resulting in increases in
lactate and citric acid; inactivated PINK1/parkin-mediated mitophagy, resulting in accumulation of damaged mitochon-
dria that are not targeted for removal via the autophagy−lysosomal system; and increases in reactive oxygen/nitrogen
species causing increased oxidative stress. A combination of these factors results in elevations in the number of methyl-
malonic acid-stressed cells, leading to mitochondrial dysfunction and cellular stress, which are factors responsible for the
development of neurodegeneration in methylmalonic acidaemia (created using biorender.com). ∆Ψm—mitochondrial
membrane potential; ATP—adenosine triphosphate; MRC—mitochondrial respiratory chain; PINK1—PTEN-induced
kinase 1; MMUT—L-methylmalonyl-CoA mutase; MMA—methylmalonic acid; MA—malonic acid; MCA—2-methylcitrate;
ROS/RNS—reactive oxygen/nitrogen species; OS—oxidative stress.
MMUT Deficiency and Mitochondrial Dysfunction
Although the mechanisms are not yet fully understood, recent evidence has demon-
strated that a deficiency in the gene encoding methylmalonyl-CoA mutase, MUT, affects
the efficient functioning of the PINK1/parkin pathway in order to remove dysfunctional
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mitochondria via the autophagy-lysosomal system, a degradation system required for the
removal of harmful cytosolic entities such as misfolded proteins, aged, and/or damaged
organelles [20,81,92]. This suggests that there may be a primary link between MMUT
deficiency, mitochondrial dysfunction, and cellular stress in the development of neurode-
generation in MMAemia.
Inactivating mutations in the MUT gene can result in a loss-of-function of the MMUT
enzyme activity, and these mutations can either be a complete (MUT0) or partial (MUT-)
loss-of-function, leading to the accumulation of toxic organic acids within the mitochon-
drial matrix, initiating mitochondrial network structural and functional abnormalities.
MMUT is expressed in various tissues, including the basal ganglia of the brain [93], how-
ever it is highly expressed within the mitochondria of kidney tubular cells, therefore the
consequences of MMUT deficiency on mitochondrial network function and homeostasis
have been investigated using these cells [92]. In MMAemia-patient kidney tubular cells, an
MMUT deficiency can result in the accumulation of damaged and dysfunctional mitochon-
dria as a consequence of deficient MMUT inactivating PINK1/parkin-mediated mitophagy,
therefore producing excessive levels of ROS and causing cellular distress [20]. In this same
study (Luciani et al., 2020), a link between MMUT deficiency and autophagy induction was
reported, suggesting that an MMUT deficiency may impair mitochondrial homeostasis and
function via compromised PINK1/parkin-directed priming of MMA-stressed mitochondria
to autophagic-lysosomal degradation [20]. Both MMA and control cells were treated with
the mitochondrial complex I inhibitor [94], rotenone, in order to induce mitochondrial
damage. This study observed, under normal and stress-induced conditions, a reduced
amount of parkin clusters and reduced translocation of parkin to damaged mitochondria
in MMA cells, in addition to mitochondrial abnormalities such as mitochondrial fragmen-
tation, reduced ∆Ψm, and impaired mitochondrial respiration and ATP generation [20].
As a consequence of the defective PINK1/parkin priming mechanisms, mutant MUT cells
fail to transport their damaged mitochondria to the autophagy-lysosomal degradation
systems, therefore triggering an accumulation of MMA-diseased mitochondria within the
cell [90]. Thus, the disrupted clearance of MMA-stressed mitochondria triggers a level of
mitochondrial dysfunction that causes cellular distress and damage.
In order to demonstrate the central role of MMUT in maintaining mitochondrial
network function and homeostasis, Chen et al. (2020) analysed a KO MUT zebrafish
model that displayed an abnormal mitochondrial morphology characterised by perturbed
mitochondrial cristae organisation, in addition to impaired mitochondrial bioenergetics,
contributing to increased mitochondrial OS [92]. This was also observed in an earlier
experimental study on rats, where chronic exposure to MMA resulted in mitochondrial
swelling and disorganised cristae of the tubulum epithelium [95]. Moreover, studies with
mutant kidney cells have demonstrated that mitochondrial homeostasis and function
can be improved by therapeutic interventions that target the PINK1/parkin pathway
by activating mitophagy-mediated degradation in order to avoid mitochondrial-derived
cellular stress and damage, as well as maintaining efficient mitochondrial quality control
mechanisms [20].
3.3.2. Lysosomal Storage Disorders
Lysosomal storage disorders (LSDs) are a heterogenous group of rare IMDs caused by
genetic mutations that cause absence or loss-of-function of lysosomal hydrolases and/or
non-lysosomal protein transporters, leading to the progressive accumulation of undigested
material within the lysosomal and/or autophagic systems, therefore affecting lysosomal
function and reducing cell survival [96]. Most LSDs display an autosomal recessive mode of
inheritance, for example Gaucher Disease (GD) and Niemann Pick Type C (NPC), although
some LSDs are inherited in an X-linked pattern, for example Mucopolysaccharidosis
Type II (MPSII) [97,98]. The clinical manifestations of LSDs vary depending on age of
onset, severity, and the specific substrate and site of accumulation, and are multisystemic
diseases characterised by hepatic, renal, cardiovascular, and pulmonary and neurological
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manifestations [98–100]. The majority of LSDs have a profound influence on the CNS and
frequently present with neurological symptoms leading to neurodegeneration in multiple
brain regions, including the cerebellum, cortex, and hippocampus [99]. Moreover, the
accumulation of undigested material within the lysosomes also affects the function of
other organelles, including the mitochondria, leading to secondary consequences such as
impaired autophagy, mitochondrial dysfunction, inflammation, and apoptosis.
Mitochondrial Dysfunction in Lysosomal Storage Disorders
Impaired mitochondrial function has been suggested as a collective pathogenic feature
of LSDs, as the majority of LSDs frequently present with primary lysosomal impairment
in addition to mitochondrial dysfunction [101]. Experimental studies have reported mi-
tochondrial morphological abnormalities, such as mitochondrial fragmentation and/or
elongation, as well as dysfunctional mitochondrial bioenergetics, as a consequence of im-
paired mitochondrial respiration, reduced MRC activity, and/or decreased ∆Ψm (Figure 8).
In mouse models of neuropathic GD, the most common LSD caused by mutations in the
glucocerebrosidase (gba) gene, which encodes for the lysosomal enzyme, glucocerebrosidase
(GCase), neurons, and astrocytes that do not express gba, were found to have defective
autophagic and proteasomal machinery, causing a primary lysosomal defect and leading
to an accumulation of dysfunctional mitochondria within the cell [102]. Furthermore,
Osellame et al. (2013) reported evidence of impaired mitochondrial function in neurons
and astrocytes of type II GD, as morphological abnormalities were indicated by small and
fragmented mitochondria [102]. The resting ∆Ψm was measured in gba KO (gba−/−) mice
models and was found to be significantly lower in comparison with mice neurons and
astrocytes derived from gba homozygous (gba+/+) and gba heterozygous (gba+/−) mutations.
gba+/+ and gba−/− neurons were incubated with oligomycin—an ATPase inhibitor —in
order to assess the function of the MRC, demonstrating that the ∆Ψm in gba+/+ neurons
was not affected by incubation with oligomycin, but was significantly reduced in gba−/−
neurons, suggesting that the reduced ∆Ψm is maintained by ATP synthase (complex V)
working in reverse, which is a mechanism implicated in PINK1 KO-associated PD. More-
over, confocal imaging of neurons and astrocytes located within the midbran indicated
significant mitochondrial fragmentation in gba−/− cells, in comparison with gba+/+ and
gba+/− cells, suggesting that GD can cause increased mitochondrial fragmentation and
MRC impairments, including reduced complex I and complex II + III activity, leading to
mitochondrial dysfunction. Interestingly, evidence has also demonstrated an association
between an absence or loss-of-function of gba and an increased risk of PD in GD patients, as
the genetic causes of familial PD are thought to induce the same biochemical and molecular
events that underlie the pathogenesis of several LSDs.
Moreover, a study carried out by Cleeter et al. (2013) identified a significant reduction
in ATP synthesis involving both MRC complex I and complex II/III-linked ADP phos-
phorylation, as a result of a 20-day incubation with a selective inhibitor of GCase activity,
conduritol-β-epoxide (CβE), with inhibited levels of GCase activity consistent with those
reported in GD patients [103]. Despite an observed significant reduction in ATP synthesis,
individual MRC protein activities were unaltered, suggesting that defective ATP synthesis
may be due to dysfunctional electron transfer in the MRC and/or defective mitochondrial
membrane. Inhibition of GCase with CβE caused mitochondrial function abnormalities
and increased OS, which are defects frequently observed in the PD brain and mitochondrial
disease [22,103]. Additionally, following CβE treatment, a significant and progressive
elevation in free radical generation was observed, which may have contributed to the
observed mitochondrial fragmentation as a result of increased OS [103].
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Figure 8. Molecular mechanisms leading to mitochondrial dysfunction in lysosomal storage disor-
ders. Lysosomal dysfunction is associated with dysregulated autophagy/mitophagy pathways, 
leading to the accumulation of dysfunctional mitochondria within the cell. Mitochondria can be 
further damaged by the accumulation of aggregated α-synuclein causing altered mitochondrial 
morphology (small, rounded fragmented and elongated mitochondria). α-synuclein accumulation 
is also associated with dysfunctional mitochondrial bioenergetics, including reduced ΔΨm and 
ATP, increases in ROS levels, and altered Ca2+ homeostasis, which are events leading to cell death. 
Impaired mitophagy also occurs as a consequence of impaired PINK1/parkin recruitment and/or 
function. Reduced recycling and the removal of mitochondria by mitophagy increases the number 
of damaged mitochondria within the cell due to reduced colocalisation of autophagosomes and mi-
tochondria (created using biorender.com). ΔΨm—mitochondrial membrane potential; ATP—aden-
osine triphosphate; ROS—reactive oxygen species; PINK1—PTEN-induced kinase 1; gba—gluco-
cerebrosidase. 
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phorylation, as a result of a 20-day incubation with a selective inhibitor of GCase activity, 
conduritol-β-epoxide (CβE), with inhibited levels of GCase activity consistent with those 
reported in GD patients [103]. Despite an observed significant reduction in ATP synthesis, 
individual MRC protein activities were unaltered, suggesting that defective ATP synthe-
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drial membrane. Inhibition of GCase with CβE caused mitochondrial function abnormal-
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to the observed mitochondrial fragmentation as a result of increased OS [103].  
Oxidative Stress in Lysosomal Storage Disorders 
Evidence of elevated OS has been reported in patient GD fibroblasts through the 
presence of an increased generation of superoxide ions from non-phagocytic NADPH ox-
idase together with protein carbonyls from augmented protein oxidation [104]. It is pos-
sible that OS may also result from an accumulation of damaged mitochondria whose ab-
errant MRC function may become a major source of ROS generation, contributing to OS-
Figure 8. Molec lar mechanisms l adi g to mitochondrial dysfunction in lysos mal storage disorders. Lysosomal dys-
function is associated with dysreg lated autophagy/mitophagy pathways, leading to the accumulation of d sfunctional
mitochondria within the cell. Mitochondria can be further damaged by the accumulation of aggregated α-synuclein causing
altered mitochondrial morphology (small, rounded fragmented and elongated mitochondria). α-synuclein accumulation is
also associated with dysfunctional mitochondrial bioenergetics, including reduced ∆Ψm and ATP, increases in ROS levels,
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impaired PINK1/parkin recruitment and/or function. Reduced recycling and the removal of mitochondria by mitophagy
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Oxidative Stress in Lysosomal Storage Disorders
Evidence of elevated OS has been reported in patient GD fibroblasts through the
presence of an increased generation of superoxide ions from non-phagocytic NADPH
oxidase together with protein carbonyls fro augmented protein oxidation [104]. It is
possible that OS may also result from an accumulation of damaged mitochondria whose
aberrant MRC function may become a major source of ROS generation, contributing to
OS-induced cellular damage [101]. Furthermore, evidence of OS has also been reported in
NPC human fibroblasts; post-mortem cerebellum; n MPS IV patient urine, plasma, and
leukocytes, where increased protein oxidation, lipid peroxidation, and DNA damage have
b en described [99]. In NPC human fibroblasts, a re uced SOD2 and/or CAT activity was
observed, as well as iminish d GSH levels, in addition to MPS IV pat ent erythrocytes
showing decreased GSH activity, suggesting the presence of ncre se OS in other LSDs.
Furthermore, mitocho drial-associated OS events are also known o e dysfunctional in
the PD brain, which may result from a loss of cerebral GSH status, which has been reported
in post-mortem studies [35].
Dysregulated Mitochondrial Biogenesis and Mitophagy in Lysosomal Storage Disorders
The accumulation of defective mitochondria may possibly be due to dysregulated mito-
chondrial biogenesis and mitophagy pathways, which have been reported in animal and cel-
lular models of several LSDs [105]. Impaired mitophagy through impaired PINK1/parkin
recruitment and/or function has recently been investigated in mouse models of GD, which
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have shown reduced colocalisation of autophagosomes and mitochondria, therefore lead-
ing to reduced recycling of damaged mitochondria in mice primary neurons [99]. This was
demonstrated in a study undertaken by Osellame et al. (2013), where gba-/- neurons failed
to recruit parkin despite a reduction in ∆Ψm. In order to assess the failed recruitment of
parkin, cells were treated with carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone
(FCCP)—an uncoupler of mitochondrial OXPHOS leading to the collapse of ∆Ψm—in
order to promote PINK1 accumulation at the OMM [102]. However, once the mitochondria
were depolarised, the gba-/- neurons showed no difference in the levels of PINK1 in compar-
ison to the controls, confirming that a reduced ∆Ψm in gba-/- neurons is not sufficiently low
enough for parkin recruitment, suggesting that ∆Ψm must be near to complete dissipation
in order to be selected for turnover. As a consequence, damaged mitochondria remain
unmarked for turnover via mitophagy, resulting in impaired and defective mitochondria
accumulating in gba-/- neurons, therefore compromising neuronal cell function. In another
study by Moren et al. (2019), GD cellular models derived from neural crest stem cells con-
taining gba+/+ and gba+/− mutations were found to increase PGC1α levels under carbonyl
cyanide-m-chlorophenyl-hydrazine (CCCP)-induced mitophagy—another mitochondrial
OXPHOS uncoupler promoting cell death [106]—therefore increasing the mitochondrial
content via the activation of mitochondrial biogenesis [107]. As a result of treatment with
CCCP, mitochondrial depolarisation led to a significant elevation in PGC1α in gba+/+ cell
lines in comparison with control and gba+/− cell lines, which is possibly a compensatory
mechanism for the underlying mitochondrial defects and GCase deficiency in GD. This
study identified that impaired turnover of depolarised mitochondria and GCase-deficient
neurons in GD are possible mechanisms that may be associated with early mitochondrial
impairments and dysfunction in this disorder.
Mitochondrial Dysfunction and α-Synuclein Aggregation in Lysosomal Storage Disorders
The accumulation of protein aggregates, such as α-synuclein, may further deteriorate
mitochondrial function and have been reported in post-mortem cerebral samples of LSD
patients [99]. Although α-synuclein accumulation is strongly associated with both sporadic
and familial forms of PD, the assessment of numerous LSD patient samples has revealed
the presence of Lewy bodies and neurotoxic intracellular accumulation of α-synuclein
in cerebral tissue, including in the cortex, hippocampus, and substantia nigra [99,108].
Interestingly, Lewy bodies containing aggregated α-synuclein have been associated with
mitochondrial fragmentation and dysfunction in several cellular models of LSDs [99]. This
was investigated by Choi et al. (2012), where brain homogenates from the cerebral cortex
of the post-mortem brain samples of patients with gba mutations were found to contain
aggregated α-synuclein [109]. This study analysed the presence of intracellular α-synuclein
inclusions using SDS-PAGE and Western blot, demonstrating that most patients with gba
mutations exhibited bands of insoluble oligomeric forms of α-synuclein, in comparison
with the controls and GD patients without gba mutations. Cerebral tissue from animal
models with neuronal variants of GD revealed disrupted mitochondrial cristae and the
presence of rounded, fragmented mitochondria associated with aggregated α-synuclein
accumulation, as well as reduced oxygen consumption and reduced ATP levels [108].
These protein aggregates have been found to colocalise with mitochondria, suggesting
that α-synuclein may cause a direct impairment to mitochondrial function, although it
has not yet been fully elucidated whether α-synuclein accumulation is a primary cause
of mitochondrial damage in LSDs or whether it is a secondary consequence caused by
increased generation of ROS and/or impaired autophagic systems [99].
In a study undertaken by Luth et al. (2014), the accumulation of α-synuclein was demon-
strated to directly inhibit MRC complex I activity, as well as reduce ∆Ψm and increasing ROS
generation and alter calcium homeostasis [110]. Therefore, these studies suggest that the accu-
mulation of protein aggregates, including α-synuclein, are risk factors for the development of
mitochondrial dysfunction in LSDs. Moreover, the presence of Lewy bodies has also been
reported in other LSDs, including the presence of phosphorylated α-synuclein in MPS III
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patient cerebral tissue samples, in addition to samples of cerebral tissue from NPC patients,
which were positive for the presence of aggregated α-synuclein [111,112]. The plasma of GD
and NPC patients, in addition to NPC lymphoblasts, were also reported to contain α-synuclein
oligomers [113,114]. LSDs are complex disorders, therefore therapeutic strategies that target
several different mitochondrial-associated molecular pathways may be beneficial for improv-
ing mitochondrial function and quality control mechanisms, particularly in neuronal cells, in
order to alleviate mitochondrial dysfunction and neurodegeneration in LSDs.
4. Therapeutic Approaches
4.1. Targeting Dysfunctional Mitochondria to Induce Mitochondrial Biogenesis
Inherited and non-communicable diseases that result in CNS disturbances are often
associated with mitochondrial dysfunction, therefore therapeutics that are capable of targeting
mitochondria in order to prevent mitochondrial-associated development of neurodegenera-
tion may be beneficial in the treatment of these disorders. Several experimental studies have
identified potential therapeutic compounds that have the capacity to induce mitochondrial
biogenesis or the generation of new, functional mitochondria within cells in order to stimulate
cellular repair and regeneration [115]. Mitochondrial biogenesis is a process that is defined as
the growth and division of pre-existing mitochondria, and is triggered by numerous environ-
mental stressors, including OS [116]. PGC1α is the most inducible and responsive member
of the PGC-1 family, and has been shown to drive mitochondrial biogenesis in response to
various environmental signals [117]. PGC1α can be directly activated via silent mating type
information regulation 2 homolog (SIRT1)-mediated deacetylation, resulting in increased
co-activation of SIRT1-targeted transcription factors, which is an important cellular mecha-
nism in order to increase mitochondrial metabolism in response to stress conditions [118].
Additionally, the phosphorylation of kinases, including AMP-dependent kinase (AMPK),
can directly regulate PGC1α activity. However, AMPK is also capable of regulating PGC1α
activity indirectly, by increasing NAD+ via increased fatty acid oxidation, therefore enhancing
SIRT1 activity and inducing SIRT1-mediated deacetylation. The activation of mitochondrial
biogenesis can be achieved via the pharmacological induction of PGC1α, which has been
demonstrated to improve oxidative metabolism and mitochondrial bioenergetics, potentially
providing neuroprotective effects and improving overall cellular function [115,117,119]. There-
fore, mitochondrial biogenesis is an interesting novel therapeutic approach in order to target
mitochondrial dysfunction in diseases that involve neurodegeneration.
4.1.1. Natural Polyphenols
Resveratrol
Natural polyphenols, including resveratrol (3,5,4′-trihydroxystilbene) and curcumin
(1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione), are produced in plants
in response to injury and stress, and are found in several food sources [120]. These redox-
active compounds have become an interesting mitochondria-targeting therapeutic in order
to preserve the structure and function of the mitochondria and neurons [121]. Polyphe-
nols exhibit antioxidant and neuroprotective properties including the ability to activate
transcription factors such as Nrf2, which are involved in the expression of antioxidant
enzymes, and can directly regulate the mitochondrial apoptosis system and induce mi-
tochondrial biogenesis in order to improve mitochondrial mass and function [121–123].
These compounds have shown many beneficial effects in the mitochondria, however they
often exhibit very low bioavailability, poor absorption, and rapid metabolism, notably
in the brain [120,124], which may compromise the effectiveness of these compounds in
neurometabolic and neurodegenerative diseases.
Several experimental studies have identified mitochondria as the key targets of resver-
atrol, as it has been shown to be a regulator of MRC function, capable of inducing mi-
tochondrial biogenesis and reducing ROS production via its interaction with SIRT1 and
AMPK via PGC1α [116,125]. Gueguen et al. (2015) identified MRC complex I as a direct
target of resveratrol action (Figure 9), resulting in an increase in its enzymatic activity
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following treatment with low doses of the compound (1–5 µM) [125]. This interaction
between MRC complex I and resveratrol results in the stimulation of key signalling path-
ways, including the SIRT1-dependent upregulation of several antioxidant enzymes in the
brain, such as SOD1 and SOD2, GPx, and CAT [125–127]. Resveratrol has been found
to promote neuronal survival via inducing apoptotic cell death, in addition to the regu-
lation of secondary consequences of disease pathogenesis, including inhibiting OS and
preventing neuro-inflammation [120,128]. In primary fibroblast cultures from patients with
early-onset PD, resveratrol treatment was found to induce apoptosis in order to efficiently
remove damaged mitochondria and misfolded proteins [129]. Increased mRNA expression
of several PGC1α target genes was also identified in parkin-mutated fibroblasts following
resveratrol treatment, which was then demonstrated to improve mitochondrial oxidative
function, while simultaneously reducing OS and increasing mitochondrial biogenesis [130].
Interestingly, resveratrol treatment resulted in increased MRC complex I and citrate syn-
thase (CS) activity—a biomarker for mitochondrial enrichment—increased ATP production
and reduced lactate concentrations, suggesting an induction of mitochondrial biogenesis.
Resveratrol is able to rapidly cross the BBB, however it should be noted that resveratrol is
rapidly metabolised and has both a low solubility and bioavailability, which may reduce
the efficacy of this potential therapeutic compound, although this may be improved with
the addition of bioenhancers or drug-delivery carriers [120,131]. In vitro animal studies
with bioenhancers have shown increased plasma concentrations of resveratrol through the
use of combination therapies, for example, combining resveratrol and hydroxypropyl-β-
cyclodextrin, which increased the solubility and absorption of this compound, in addition
to nanoformulations of resveratrol, which increased its surface area for absorption [120].
However, the effects of bioenhancers have not yet been widely studied in humans.
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Figure 9. Mitochondrial respiratory chain complex I is a direct target of resveratrol. The interaction 
between mitochondrial respiratory chain complex I and resveratrol results in the simulation of 
SIRT1, leading to SIRT1-dependent upregulation of several antioxidants in the brain, including 
SOD1, MnSOD, GPx, and CAT. Resveratrol treatment promotes neuronal survival in PD (created 
using biorender.com). C1–C5—MRC complexes 1–5; SIRT1—silent mating type information regu-
lation 2 homolog; SOD1—superoxide dismutase 1; MnSOD—manganese superoxide dismutase; 
GPx—glutathione peroxidase; CAT—catalase; OS—oxidative stress; ROS—reactive oxygen species; 
PD—Parkinson’s disease. 
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Curcumin has a wide range of health promoting functions, including cytoprotective 
and neuroprotective properties, in addition to its favorable absorption, bioavailability, 
and long half-life in the CNS [132]. The long half-life of curcumin in the CNS (6–7 h in 
plasma) is thought to be due to its amphiphilic nature and a high concentration of lipids 
within the brain, meaning that this compound may be beneficial in patients who present 
neurologically [132,133]. Several experimental studies have suggested that curcumin can 
interact simultaneously with multiple molecular targets, resulting in a cascade of bio-
chemical and molecular events and activating multiple signalling molecules, such as 
AMPK, SIRT1, and Nrf2, and therefore protecting the cells from oxidative injury by in-
creasing mitochondrial mass and protein expression elicited by the induced mitochon-
drial biogenesis [119,120,134]. Curcumin has also been shown to exhibit a protective effect 
against mitochondrial dysfunction and apoptosis, in addition to improving oxygen con-
sumption rates, increasing cell viability, and ΔΨm in PINK1-deficient cells [135]. Models 
of PD have also demonstrated the potential neuroprotective effects of curcumin, as rat 
SNpc neurons were shown to be protected from apoptosis following curcumin treatment, 
leading to increased dopamine levels within the striatum, and reduced cytotoxicity and 
cell viability [135–137]. Curcumin has been shown to prevent cytochrome c release and 
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Curcumin
Curcumin has a wide range of health promoting functions, including cytoprotective
and neuroprotective properties, in addition to its favorable absorption, bioavailability, and
long half-life in the CNS [132]. The long half-life of curcumin in the CNS (6–7 h in plasma)
is thought to be due to its amphiphilic nature and a high concentration of lipids within the
brain, meaning that this compound may be beneficial in patients who present neurologi-
cally [132,133]. Several experimental studies have suggested that curcumin can interact
simultaneously with multiple molecular targets, resulting in a cascade of biochemical and
molecular events and activating multiple signalling molecules, such as AMPK, SIRT1, and
Nrf2, and therefore protecting the cells from oxidative injury by increasing mitochondrial
mass and protein expression elicited by the induced mitochondrial biogenesis [119,120,134].
Curcumin has also been shown to exhibit a protective effect against mitochondrial dysfunc-
tion and apoptosis, in addition to improving oxygen consumption rates, increasing cell
viability, and ∆Ψm in PINK1-deficient cells [135]. Models of PD have also demonstrated
the potential neuroprotective effects of curcumin, as rat SNpc neurons were shown to be
protected from apoptosis following curcumin treatment, leading to increased dopamine
levels within the striatum, and reduced cytotoxicity and cell viability [135–137]. Curcumin
has been shown to prevent cytochrome c release and inhibit α-synuclein-induced neuronal
toxicity and death in a PC12 cell model of PD [138–140]. Moreover, curcumin treatment was
demonstrated to be beneficial in an NPC1 mice model, where triple combination therapy
involving curcumin, miglustat (targets sphingolipid synthesis and storage in GD and NPC),
and ibuprofen (reduces CNS inflammation) was found to enhance neuroprotection and cell
survival, in addition to ameliorating the autophagic flux function [141].
4.1.2. Bioactive Quinones
Coenzyme Q10 (CoQ10)
CoQ10 is a potent antioxidant and essential cofactor carrying electrons from complexes
I and II to complex III of the MRC, and is a well-known activator of PGC1α [142,143].
CoQ10 has been suggested to have a role as a neuroprotective agent, as this lipophilic
antioxidant has been shown to improve cognitive function, facilitate ATP synthesis, and
upregulate mitochondrial function in neurodegeneration [144]. A study carried out by
Somayajulu et al. (2005) investigated the role of CoQ10 as a neuroprotective agent when
neuronal cells were exposed to hydrogen peroxide (H2O2)-induced OS [145]. In human
neuroblastoma (SH-SY5Y) cells pre-treated with water-soluble CoQ10 following H2O2
treatment, a significant reduction in mitochondrial ROS generation, preserved ∆Ψm, in-
creased mitochondrial ATP production, and the prevention of mitochondrial membrane
collapse were observed in comparison with the control mitochondria. This suggests that
CoQ10 can act as a potent antioxidant at the mitochondrial level, as CoQ10 has been demon-
strated to stabilise the mitochondrial membrane and increase mitochondrial numbers as a
consequence of H2O2-induced OS, which may be due to the ability of CoQ10 to increase
PGC1α signalling [142,145,146]. Studies with senescence-accelerated mouse (SAM) mod-
els have revealed that a diet supplemented with CoQ10 can induce pathways involving
SIRT1, SIRT3, and PGC1α, preventing mitochondrial deterioration by increasing OS re-
sistance [143]. In this study, Western blot analyses demonstrated that CoQ10 induced the
deacetylation and activation of PGC1α and SOD2 via SIRT1 and SIRT3, therefore increasing
mitochondrial mass and function via PGC1α-activated mitochondrial biogenesis. This
study also identified that increased levels of cyclic adenosine monophosphate (cAMP)
can mediate the metabolic effects of PGC1α on mitochondrial function and biogenesis via
the increased expression of PGC1α. These findings provide biochemical evidence that
CoQ10 is capable of regulating mitochondrial activity by enhancing the activity of the
cAMP-AMPK-SIRT1-PGC1α-pathway. Furthermore, at the inner mitochondrial membrane
level, CoQ10 has been acknowledged as a modulator of mPTP, and has been demonstrated
to prevent the opening of the mPTP in order to prevent ∆Ψm collapse, therefore inhibiting
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mitochondrial-mediated apoptosis [147–149]. A summary of the neuroprotective effects of
the bioactive quinones are outlined in Figure 10.
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effects of PQQ were studied in a mouse rotenone-induced PD model, where PQQ was 
found to protect SH-SY5Y cells and dopaminergic neurons from neurotoxicity and to pre-
vent mitochondrial dysfunction through the promotion of mitochondrial biogenesis, in 
addition to preventing motor deficits and reducing dopaminergic neuronal loss in the 
SNpc and dopamine depletion in the striatum [153]. PQQ has been shown to be a prom-
ising therapeutic candidate in animal models and cell cultures in order to ameliorate mi-
tochondrial dysfunction through mitochondrial biogenesis induction, and this compound 
has therapeutic potential, as PQQ is water-soluble and low dietary concentrations are eas-
ily absorbed in the intestines, in comparison with natural polyphenols, which are water-
insoluble and have poor absorption [151]. 
Idebenone 
Idebenone (2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone) is a 
synthetic analogue of CoQ10 that is active in the CNS and is capable of crossing the BBB 
[154–157]. It is an important antioxidant that has demonstrated a neuroprotective role in 
several neurological disorders, including PD. The pharmacological function of idebenone 
is centred on the activation of the electron transfer system, in addition to the reduction of 
non-respiratory oxygen consumption after conversion to its reduced, ubiquinol form by 
the MRC complex I [154]. Idebenone has also been found to be successful at inhibiting 
oxidative processes, such as lipid peroxidation. In a study carried out by Yan et al. (2019), 
idebenone treatment (100 mg/kg) in mice was shown to improve MPTP-induced dopa-
minergic neuronal death and the neurological deficits associated with PD, in addition to 
diminishing the inflammatory response by reducing the expression of several proinflam-
matory cytokines in the striatum and substantia nigra [156]. Moreover, in vitro studies 
have also demonstrated that treatment with idebenone can protect against MPTP-induced 
motor dysfunction and reduce neuronal death in the substantia nigra and striatum.  
 Figure 10. Summary of the neuroprotective effects of the following bioactive quinones: coenzyme Q10, pyrroloquinoline
quinone, and idebenone. These compounds have been reported in the literature as having roles as neuroprotective agents,
in addition to upregulating the mitochondrial mass and function in neurodegeneration (created using biorender.com).
CoQ10—coenzyme Q10; PQQ—pyrroloquinoline quinone; ∆Ψm—mitochondrial membrane potential; ROS—reactive
oxygen species; ATP—adenosine triphosphate; mtDNA—mitochondrial DNA; PGC1α—peroxisome proliferator-activated
receptor gamma coactivator 1-alpha; NRF1 + 2—nuclear respiratory factor 1 + 2.
Pyrroloquinoline Quinone (PQQ)
PQQ, a natural redox cofactor, has been reported to stimulate mitochondrial biogene-
sis and has been associated with several health benefits due to its antioxidant properties,
including improved mitochondrial function, energy utilization, and longevity, in addi-
tion to inhibiting apoptosis, providing protection from ROS, and improving neurologic
functions in animal and cellular models [150–152]. A study carried out in mouse hepa-
tocytes (Hepa1-6 cells) by Chowanadisai (2013) demonstrated that PQQ treatment was
capable of increasing the mitochondrial content and stimulating mitochondrial biogenesis,
indicated by an increased CS and cytochrome c activity, mtDNA content, and cellular
oxygen respiration [151]. PQQ exposure was shown to promote phosphorylation of cAMP
response element-binding protein (CREB), activating the PGC1α promoter, therefore in-
creasing PGC1α mRNA transcription and protein expression, in comparison with the
post-translation regulation of PGC1α by resveratrol. In addition, PQQ exposure to the
Hepa1-6 cells was also found to increase the activation of NRF1 and 2. Moreover, the
neuroprotective effects of PQQ were studied in a mouse rotenone-induced PD model,
where PQQ was found to protect SH-SY5Y cells and dopaminergic neurons from neurotox-
icity and to prevent mitochondrial dysfunction through the promotion of mitochondrial
biogenesis, in addition to preventing motor deficits and reducing dopaminergic neuronal
loss in the SNpc and dopamine depletion in the striatum [153]. PQQ has been shown
to be a promising therapeutic candidate in animal models and cell cultures in order to
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ameliorate mitochondrial dysfunction through mitochondrial biogenesis induction, and
this compound has therapeutic potential, as PQQ is water-soluble and low dietary con-
centrations are easily absorbed in the intestines, in comparison with natural polyphenols,
which are water-insoluble and have poor absorption [151].
Idebenone
Idebenone (2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone) is a syn-
thetic analogue of CoQ10 that is active in the CNS and is capable of crossing the BBB [154–157].
It is an important antioxidant that has demonstrated a neuroprotective role in several neu-
rological disorders, including PD. The pharmacological function of idebenone is centred
on the activation of the electron transfer system, in addition to the reduction of non-
respiratory oxygen consumption after conversion to its reduced, ubiquinol form by the
MRC complex I [154]. Idebenone has also been found to be successful at inhibiting ox-
idative processes, such as lipid peroxidation. In a study carried out by Yan et al. (2019),
idebenone treatment (100 mg/kg) in mice was shown to improve MPTP-induced dopamin-
ergic neuronal death and the neurological deficits associated with PD, in addition to
diminishing the inflammatory response by reducing the expression of several proinflam-
matory cytokines in the striatum and substantia nigra [156]. Moreover, in vitro studies
have also demonstrated that treatment with idebenone can protect against MPTP-induced
motor dysfunction and reduce neuronal death in the substantia nigra and striatum.
4.1.3. PPARγ Agonists
Numerous animal and cellular models and clinical studies have shown that PPARγ-
agonists may represent a novel therapy for the treatment of several neurodegenerative
conditions [158]. Drugs that activate PPARγ, for example thiazolidinediones (TZDs),
commonly used for the treatment of diabetes mellitus, may be a potential treatment for neu-
rodegenerative disorders due to their antioxidant, anti-inflammatory, and anti-apoptotic
properties [46]. PPARγ activation was found to upregulate mitochondrial biogenesis; in-
crease antioxidant defenses, ∆Ψm, and transcription factors, including PGC1α and Nrf1/2;
and regulate autophagy. In a human neuroblastoma SH-SY5Y cell model, rosiglitazone—a
TZD and PPARγ-agonist [159]—was shown to induce antioxidant enzymes, such as SOD
and CAT, and protect against neuronal damage induced by acetaldehyde in order to pre-
vent the increased generation of intracellular ROS and apoptotic cell death [160]. Promoters
of these antioxidant enzymes contain a PPAR response element, therefore rosiglitazone may
potentially regulate the expression of SOD and CAT to protect the cells from ROS-induced
damage. This study also showed that in acetylaldehyde-treated cells, rosiglitazone regu-
lates B-cell lymphoma 2 (Bcl-2) expression, a cellular protein with anti-apoptotic properties
associated with mitochondrial membrane permeability stabilisation, thereby maintaining
mitochondrial integrity by suppressing cytochrome c release and inhibiting apoptosis.
Pioglitazone treatment—an alternative TZD—was found to increase mtDNA content, the
expression of nuclear-encoded MRC subunit proteins, and complex I (NADH: ubiquinone
oxidoreductase) and complex IV (cytochrome c oxidase) activities in the human neuron-
like NT2 cell line [46,161]. Moreover, in rat cortical slices and astrocytes, the PPAγ ligand
15D-PGJ2 and rosiglitazone demonstrated a neuroprotective effect by inhibiting cerebral
oxidative damage following repeated stress, in addition to replenishing cerebral ATP levels
and preventing impaired glutamate uptake [162]. Pre-clinical studies in animal models of
PD have shown that rosiglitazone protects dopaminergic neurons and reduces neuroinflam-
mation [119]. However, these drugs are often associated with adverse outcomes, including
increased risk of heart failure and obesity [158].
It has been reported in recent studies that decanoic acid (C10) can interact with PPARγ
in order to stimulate mitochondrial biogenesis and increase the antioxidant status in several
neurological disorders [163]. The medium chain triglyceride (MCT)-based ketogenic diet
(KD) has been found to be an effective treatment for neurodegenerative diseases and IMDs,
as C10 has been shown to improve mitochondrial function and energy metabolism in
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patients with mitochondrial disorders and in neuronal cell models of these diseases [164].
In a study by Hughes et al. (2014), SH-SY5Y cells and cultured human skin fibroblasts
were exposed to 250 µM C10, which stimulated significant increases in CS activity, as well
as PPARγ-dependent increases in neuronal mitochondrial content, as indicated by the
increased MRC complex I and CAT activities [165]. Moreover, the incubation of HT22
hippocampal murine neurons with C10 and β-hydroxybutyrate (βHB)—a ketone body—
resulted in the upregulation of the MRC in comparison with the control cells, indicated
by significant elevations of the SIRT1 and MRC complex I + III and complex IV enzyme
activities. The activity of the CS enzyme was also significantly elevated in the treated HT22
cells, suggesting an induction of mitochondrial biogenesis and a probable increase in mito-
chondrial function and mass. As C10 is a medium chain fatty acid, it is able to efficiently
cross the BBB where it can be oxidised via mitochondrial β-oxidation in the brain, therefore
C10 may be a beneficial treatment for patients with neurodegeneration [166]. However,
co-supplementation of C10 and octanoic acid (C8) in the KD should be considered, as the
presence of C8 enhances the effect of C10 by decreasing its metabolism via β-oxidation and
therefore improving the efficacy of this potential treatment [163].
4.2. Targeting Nrf2-ARE Pathway
One way in which the cell regulates its endogenous antioxidant capacity is via the
activation of the transcription factor, Nrf2 [25]. The overexpression of Nrf2 or small
molecule Nrf2 activators have been demonstrated to protect the CNS from oxidative
damage by increasing the endogenous antioxidant capacity of the brain, and there are
several Nrf2 activators undergoing clinical research for their effect on neurodegeneration
outlined in the review by Robledinos-Antón et al. (2019) [167]. Therefore, the Nrf2-ARE
pathway may be a potential therapeutic target in order to prevent the progression of
neurodegeneration in various neurodegenerative and metabolic disorders [25,168]. For the
purpose of this section, we will describe two examples of activators of Nrf2.
4.2.1. Chrysin
Chrysin (5,7-dihydroxyflavone) is a bioactive flavonoid that is naturally found in
fruits, vegetables, and medicinal plants [169]. It has several biological properties, includ-
ing antioxidant, anti-inflammatory, anti-apoptotic, and neuroprotective effects [169,170].
Although the mechanisms of Nrf2 activation by chrysin are not yet well-understood, ev-
idence has revealed that chrysin can increase the expression and transcriptional activity
of Nrf2, which in turn promotes the upregulation of the Nrf2-ARE pathway, resulting in
an elevation in the expression of several antioxidant and phase II detoxifying enzymes,
including heme oxygenase-1 (HO-1), SOD, and CAT. Studies with Nrf2 KO mice models
have reported a greater loss of dopamine transporter levels within the striatum following
1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (MPTP) treatment, a pharmacologically in-
duced model of PD, inducing neurotoxicity [171]. Mice astrocytes overexpressing Nrf2
were found to completely reverse dopaminergic neuronal loss in the substantia nigra
associated with MPTP treatment, suggesting that the activation of the Nrf2-ARE pathway
in astrocytes may be sufficient to protect neurons from MPTP-induced neurotoxicity. This
may alleviate the effects of OS in neurodegeneration, as neurons frequently depend on
astrocytes for protection against OS due to increased activation of Nrf2-ARE-dependent
gene expression in the latter cells [25,168]. A study undertaken by Thangarajan et al. (2016)
discovered that the oral administration of chrysin (50 mg/kg) for 14 days in rats signifi-
cantly improved behavioural deficits; regulated MRC complex I, II, IV, and V activities;
diminished OS markers, including lipid peroxidation and protein carbonyls; inhibited
apoptosis and significantly elevated the cellular antioxidant status (SOD, CAT, and GSH)
in the striatal mitochondria [172]. This suggested that chrysin treatment may be beneficial
for enhancing the survival of striatal neurons. However, similar to other natural flavonoids,
chrysin has a low bioavailability, poor absorption, and is rapidly metabolised, therefore a
combined pre-treatment of chrysin and protocatechuic acid (PCA)—another polyphenolic
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compound—has been studied in several in vivo and in vitro models. PCA has been shown
to enhance the neuroprotective effects of chrysin in PC12 cells by reducing the MPTP-
induced loss of SNpc dopaminergic neurons in mice, resulting in a greater cell viability,
decreased lactate dehydrogenase (LDH) release, and inhibition of lipid peroxidation, in
addition to inhibiting neuronal loss, increasing striatum dopamine levels, and restoring
behavioural deficits in PD animal models [170,172]. Chrysin and PCA treatment was also
found to significantly increase the transcriptional activity of Nrf2-responsive promoters
and Nrf2 protein expression, triggering downstream regulation of the antioxidant enzymes,
including increased intracellular SOD and CAT activity, in addition to a reduction in MDA
levels, a marker of lipid peroxidation [173]. These findings indicate a potential neuro-
protective role of chrysin combination therapy by reducing OS and providing enhanced
antioxidant neuroprotection in neurodegenerative disorders.
4.2.2. Fumaric Acid Esters
Fumaric acid esters (FAEs) are a class of electrophiles that have been found to be
neuroprotective in animal and cellular models of neurodegeneration via the activation of
the Nrf2-ARE pathway [25]. In vivo evidence has demonstrated that dimethylfumarate
(DMF), a pharmacological Nrf2 activator that has been shown to successfully reduce OS
in multiple sclerosis (MS), may also have beneficial effects in PD [25,170,174]. In vitro
studies have shown that DMF and its bioactive metabolite, monomethylfumarate (MMF),
covalently modify Keap1 resulting in the accumulation of Nrf2, leading to the upregulation
of Nrf2-dependent genes [175,176]. In a study undertaken by Lastres-Becker et al. (2016), a
mice model of α-synucleinopathy indicated that DMF can target Nrf2 at the basal ganglia
and can protect nigral dopaminergic neurons from α-synuclein toxicity, thus preventing
neuronal cell death [176]. Daily oral DMF administration in this mouse model was also
demonstrated to reduce astrocytosis and microgliosis, as well as prevent behavioral deficits.
However, this protection was found to be absent in Nrf2 KO mice, indicating that DMF
targets Nrf2 in order for DMF to exert its neuroprotective properties. Moreover, DMF and
MMF treatment in animal and primary cultures of CNS cells have been reported to increase
the nuclear levels of Nrf2, resulting in increases in the cellular redox potential, GSH and
ATP levels, and ∆Ψm [175]. In neurons and astrocytes, DMF and MMF were found to be
cytoprotective against OS-induced cellular injury and death, in addition to significantly
improving cell viability via upregulation of the Nrf2-dependent antioxidant response,
indicated by the intracellular regulation of GSH [176–178]. Other studies have demon-
strated improvements in mitochondrial function following DMF and MMF treatment by
upregulating mitochondrial biogenesis in an Nrf2-dependent manner [175].
4.3. Targeting Impaired Mitophagy and/or Autophagy
Evolving studies have provided new insights into how dysfunctional autophagy may
result in mitochondrial dysfunction and cellular stress, as well as the association between
mitophagy and cellular OS in the development and progression of neurodegeneration [179].
Therefore, impaired autophagic function may be a potential mitochondria-targeted ther-
apeutic in order to prevent mitochondrial dysfunction and improve neurodegenerative
aetiology in neurodegenerative diseases. Several therapeutic targets and compounds have
been identified that are known to stimulate autophagy/mitophagy.
4.3.1. Deubiquitinases
The ubiquitin-proteasome system (UPS) is often disturbed in many neurodegenerative
diseases, demonstrating a potential therapeutic target [26]. A potential key target within this
system are the deubiquitinating enzymes (DUBs), which function to catalyse the cleavage
of ubiquitin from target proteins in addition to regulating proteasome activity [26,180,181].
Several DUBs have been implicated in the progression of neurodegeneration in a number of
animal and cellular models, and are interesting novel therapeutic targets against neurode-
generation as they have been found to induce mitophagy in the absence of parkin/PINK1, in
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order to prompt mitochondrial clearance. Firstly, modulation of the DUB ubiquitin-specific
peptidase 14 (USP14) has been demonstrated to affect mitophagy via induction of autophagy
and by enhancing proteasome-mediated mitochondrial membrane rupture [26]. USP14 is
an attractive target as it can be specifically inhibited by IU1, a non-toxic small molecule that
binds to the USP14 catalytic domain to prevent the binding of the substrate to the enzyme,
resulting in an increased proteasome activity and enhanced mitophagy [26,182]. In an
in vivo Drosophila PD model with a PINK1/parkin mutant phenotype, USP14 knockdown
or pharmacological inhibition restored mitochondrial function and increased mitochon-
drial clearance in neuronal cells [26]. USP14 inhibition has also been shown to increase
autophagosome/autolysosome formation and enhances mitophagy in a human dopamin-
ergic cell line [183,184]. USP30 inhibition is another DUB that may be an attractive target,
as USP30 KO has been shown to increase mitophagy in human cell lines overexpressing
parkin [185]. USP30 is localised to the OMM and USP30 overexpression was found to
prevent parkin-driven mitophagy. However, reducing the activity of USP30 enhanced the
mitochondrial degradation in neurons, in addition to rescuing defective mitophagy and
improving mitochondrial integrity in PINK1 and parkin-deficient Drosophila models. USP30
KO in Drosophila was also found to protect dopaminergic neurons, therefore improving
defective dopamine levels, motor function, and organism survival.
4.3.2. Trehalose
Trehalose, a natural, non-toxic disaccharide, has been reported to function as a mam-
malian target of a rapamycin (mTOR)-independent inducer of autophagy and can protect the
cell from several environmental stressors [186,187]. It has been demonstrated to relieve mito-
chondrial and neuronal cell damage through its antioxidative and mitophagy-inducing effects,
as well as displaying anti-apoptotic effects through ameliorating mitochondrial dysfunction
and restoring the autophagic flux. The effects of trehalose were analysed in a mouse model
of manganese-induced mitochondrial dysfunction and neuronal cell damage by Liu et al.
(2019), where trehalose was shown to inhibit OS-induced mitochondrial dysfunction, such as
ATP depletion and reduced ∆Ψm, via induction of mitophagy, demonstrating a protective
role in damaged neurons [188]. Moreover, trehalose is able to activate transcription factor
EB (TFEB), the master regulator of the autosomal-lysosomal degradation pathway, via Akt
inhibition—a negative regulator of TFEB—which has been widely demonstrated to ameliorate
the pathology in LSDs and neurodegenerative disorders [189]. The clearance of protein ag-
gregates was augmented in trehalose-treated PC12 cells expressing mutant α-synuclein, and
parkin deficient mice given trehalose-treated drinking water were shown to have increased
autophagy and GSH levels together with a reduction in dopaminergic cell death [186,190].
Trehalose has been shown to target the brain when administrated orally in mice, slowing
disease progression and extending survival in MPS IIIB mice models, in addition to improving
behavioural disturbances and neuropathological features of this LSD [191]. This treatment
was also shown to promote autophagic flux in the cortex and cerebellum of MPS IIIB mice,
therefore increasing the clearance of autophagic vacuoles.
A summary of the therapeutic strategies capable of alleviating mitochondrial dysfunc-
tion in neurodegeneration are outlined in Supplementary Table S1.
5. Conclusions
Mitochondrial dysfunction has been implicated in the pathophysiology of several in-
herited and non-communicable disorders that typically present neurologically, and has been
suggested as a key event leading to the development of neurodegeneration. Thus, the devel-
opment of mitochondrial-targeted therapies represents important novel therapeutic targets
that have the potential to restore mitochondrial function, while simultaneously maintaining
neuronal cell integrity and function, promoting neuronal cell survival and preventing neurode-
generation. The therapies discussed in this review are associated with targeting mitochondrial
molecular pathways, in order to alleviate mitochondrial dysfunction and CNS disturbances, in
addition to augmenting the antioxidant capacity of the cell. In general, these therapies demon-
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strated significant improvements in mitochondrial function and neuronal cell viability in
several human, animal, and cellular models, indicating that therapeutic approaches that target
mitochondrial-associated molecular pathways may be beneficial for preventing mitochondrial
dysfunction in neurodegeneration. Although numerous studies have identified the favourable
effects of these candidate therapies, a number of issues associated with BBB transport still
remain, such as the low bioavailability and solubility of some of these compounds, which may
affect their therapeutic efficacy. Therefore, before these therapies can be offered as potential
therapeutic agents, further research is required in order to determine the efficacy and safety
of these candidate therapies, particularly for inherited neurometabolic disorders.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/ijms222111444/s1.
Author Contributions: Conceptualization, L.T. and I.P.H.; writing—original draft preparation and
figures preparation, L.E.M.; writing—review and editing, L.E.M., E.D., L.T. and I.P.H.; supervision—
E.D., L.T. and I.P.H. All authors have read and agreed to the published version of the manuscript.
Funding: This research received no external funding.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: Not applicable.
Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations
AdoCbl 5′-deoxyadenosylcobalamin







Bcl-2 B-cell lymphoma 2
C8 Octanoic acid
C10 Decanoic acid
cAMP Cyclic adenosine monophosphate
CAT Catalase
CCCP Carbonyl cyanide-m-chlorophenyl-hydrazine
CNS Central nervous system
CoQ10 Coenzyme Q10
Complex I NADH: ubiquinone oxidoreductase
Complex II Succinate dehydrogenase
Complex III Ubiquinol-cytochrome c oxidoreductase
Complex IV Cytochrome c oxidase
Complex V ATP synthase






ETC Electron transport chain










IMD Inherited metabolic disorder
iPSC Induced pluripotent stem cell
KD Ketogenic diet
Keap1 Kelch-like ECH-associated protein 1
KO Knockout
LDH Lactate dehydrogenase
LSD Lysosomal storage disorder
MA Malonic acid
MCA 2-methylcitrate
MCT Medium chain triglyceride





MnSOD Manganese superoxide dismutase
MPS Mucopolysaccharidosis
MPTP 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine
mPTP Mitochondrial permeability transition pore




NAD+ Nicotinamide adenine dinucleotide
NCD Non-communicable disease
NPC Niemann Pick Type C
Nrf1 Nuclear respiratory factor 1
Nrf2 Nuclear factor erythroid 2-related factor
NQO1 NADH quinone oxidoreductase





PGC1α Peroxisome proliferator-activated receptor gamma coactivator 1-alpha
PINK1 PTEN-induced kinase 1
PPARγ Peroxisome proliferator-activated receptor gamma
PPQ Pyrroloquinoline quinone
PTEN Phosphatase and tensin homolog
ROS Reactive oxygen species
RNS Reactive nitrogen species
SAM Senescence-accelerated mouse
Ser/Thr Serine/threonine
SIRT Silent mating type information regulation 2 homolog
SNpc Substantia nigra pars compacta
SOD Superoxide dismutase
TCA cycle Tricarboxylic acid cycle




VDAC1 Voltage-dependent anion-selective channel 1
∆Ψm Mitochondrial membrane potential
βHB β-hydroxybutyrate
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